Tag Archives: biopharma companies

Our Health Care Ecosystem

Meekers

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by U.S. biopharmaceutical companies. It is the first step on a path toward bringing much needed treatments to patients. However, with the current focus on the cost of health care, regulatory approval is not the final hurdle. Increasingly, the ability of patients to access new therapies is determined by those who pay for the treatments. Skyrocketing development costs, concerns about the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

It Takes a Village: The New Pharma-VC Model for Biotech Investing

bif-hall

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

What Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?

deborah

The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion.[i] This significant economic impact is due to the high value-added nature of the sector, its extensive supply chain relationships, and high-wage jobs. As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,